Mitokinin is a biotechnology company, developing targeted therapies for mitochondria-associated disorders, with particular focus on parkinsons disease and certain forms of cardiomyopathy.
Based on the research conducted by the UCSF team led by Shokat, a Howard Hughes Medical Institute Investigator and Nicholas Hertz Ph-D also the co-founder of the company.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/mitokinin-llc” connections=”true” suffix=””]
Mitokinin is using a medicinal chemistry effort to generate kinetin analogs optimized for activating PINK1. PINK1 a mitochondrial serine/threonine-protein kinase which causes the parkin protein to bind to depolarized mitochondria to induce autophagy of those mitochondria as they are linked with neurodegeneration.
Recover your password.
A password will be e-mailed to you.